SCHEMBL6397407

SCHEMBL6397407

Cc1ccc(C(=O)O)cc1-c1ccc(/C=C2\NC(=O)N(c3ccccc3)C2=O)o1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 11/20 1.00
POLB P06746 10/20 1.00
ALDH1A1 P00352 10/20 1.00
MEN1 O00255 10/20 1.00
KMT2A Q03164 10/20 1.00
MAPT P10636 10/20 1.00
KDM4E B2RXH2 9/20 1.00
CTDSP1 Q9GZU7 7/20 1.00
APEX1 P27695 7/20 1.00
RECQL P46063 6/20 1.00
DNMT1 P26358 3/20 1.00
HPGD P15428 3/20 1.00
PSMD14 O00487 1/20 1.00
MMP2 P08253 1/20 1.00
RAB9A P51151 2/20 0.68
NPC1 O15118 1/20 0.68
SENP8 Q96LD8 1/20 0.68
SENP7 Q9BQF6 1/20 0.68
SENP6 Q9GZR1 1/20 0.68
L3MBTL1 Q9Y468 7/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6397410 1.00 TDP1 (1.00) TDP1POLBALDH1A1MEN1KMT2A
SCHEMBL30115002 0.82 POLB (0.70) TDP1POLBALDH1A1MEN1KMT2A
SCHEMBL28362136 0.79 EP300 (0.66) TDP1POLBALDH1A1MEN1KMT2A
SCHEMBL5143034 0.79 POLB (0.65) TDP1POLBALDH1A1MEN1KMT2A
SCHEMBL5143032 0.79 POLB (0.65) TDP1POLBALDH1A1MEN1KMT2A
SCHEMBL6397790 0.77 MAPT (0.62) TDP1POLBALDH1A1MEN1KMT2A
SCHEMBL6397787 0.77 MAPT (0.62) TDP1POLBALDH1A1MEN1KMT2A
SCHEMBL31358757 0.76 MEN1 (1.00) TDP1POLBALDH1A1MEN1KMT2A
SCHEMBL6395805 0.75 POLB (0.84) TDP1POLBALDH1A1MEN1KMT2A
SCHEMBL6395803 0.75 POLB (0.84) TDP1POLBALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050282840-A1 Methods of modulating neurotrophin-mediated activity PAINCEPTOR PHARMA CORPORATION (CA) 2005-12-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050282840-A1 Methods of modulating neurotrophin-mediated activity NGF, BDNF, NTRK2 TDP1 1996/4885POLB 2945/4885ALDH1A1 2413/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.